Co-Diagnostics regains Nasdaq compliance; preliminary cash $11.9M as of Dec 31, 2025

Co-Diagnostics, Inc.

Nasdaq notified Co-Diagnostics (CODX) of compliance with $1.00 bid price rule; trading resumes March 11, 2026.
Nasdaq Hearing Panel closed; one-year Discretionary Panel Monitor imposed through March 9, 2027.
If bid price falls below $1.00 for 30 consecutive trading days, no 180-day cure period; delist determination possible.
Preliminary cash and cash equivalents estimated at $11.9M as of December 31, 2025; unaudited and subject to adjustment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.